Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario
An. bras. dermatol
;
96(4): 458-471, July-Aug. 2021. tab
Article
Dans Anglais
| LILACS
| ID: biblio-1285098
ABSTRACT
Abstract Cutaneous T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders, characterized by infiltration of the skin by mature malignant T cells. Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, accounting for more than 60% of cases. Mycosis fungoides in the early-stage is generally an indolent disease, progressing slowly from some patches or plaques to more widespread skin involvement. However, 20% to 25% of patients progress to advanced stages, with the development of skin tumors, extracutaneous spread and poor prognosis. Treatment modalities can be divided into two groups skin-directed therapies and systemic therapies. Therapies targeting the skin include topical agents, phototherapy and radiotherapy. Systemic therapies include biological response modifiers, immunotherapies and chemotherapeutic agents. For early-stage mycosis fungoides, skin-directed therapies are preferred, to control the disease, improve symptoms and quality of life. When refractory or in advanced-stage disease, systemic treatment is necessary. In this article, the authors present a compilation of current treatment options for mycosis fungoides and Sézary syndrome.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Tumeurs cutanées
/
Lymphome T cutané
/
Mycosis fongoïde
/
Syndrome de Sézary
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
An. bras. dermatol
Thème du journal:
Dermatologie
Année:
2021
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Private Institution/BR
/
Universidade de São Paulo/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS